Remove Blogging Remove Presentation Remove Pricing Remove San Diego
article thumbnail

Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout

Xconomy

There’s nothing abstract about a 20 percent jump in a company’s stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society for Clinical Oncology presentations; the meeting starts in two weeks in Chicago. Read more » Reprints | Share:

Pricing 62
article thumbnail

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

Xconomy

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xconomy Award Finalists In The Eye Of the National Drug Price Debate

Xconomy

Last week, the first genetically modified cell therapy came to market with a price tag of $475,000. It’s no surprise, then, that several finalists for the first Xconomy Awards , to be presented September 26 in.

Pricing 49
article thumbnail

Biopharma Execs Remain Optimistic Despite Political Headwinds

Xconomy

Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. In turn, pricing pressure is also a concern as corporates and investors plan for the year ahead,”. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020.

Pricing 78
article thumbnail

Bio Roundup: Cancer Wishes and Shopping Lists, Allergan Pricing & More

Xconomy

As part of the Obama administration’s “cancer moonshot” program, a panel of scientists this week presented a set of broad, ambitious recommendations to speed up the pace of cancer research, treatment, and prevention. What do cancer experts want? The moon, perhaps.

Pricing 40
article thumbnail

Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results

Xconomy

San Diego-based Retrophin said that its drug, sparsentan, outperformed another drug sometimes used to manage a rare kidney disease, called focal segmental glomerulosclerosis (FSGS), in a Phase 2 clinical trial. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. on the Nasdaq.

article thumbnail

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

Xconomy

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson.

News 57